Podcasts

Sponsored Join Now

What’s New with Feline Diabetes with Dr. Ellen Behrend, PhD, DACVIM | VETgirl Veterinary Continuing Education Podcasts

July 2024

In this VETgirl veterinary continuing education podcast, we interview Dr. Ellen Behrend, VMD, PhD, DACVIM on what’s new with feline diabetes!  Tune in to learn what’s new in the treatment of diabetes mellitus in cats [specifically with sodium-glucose co-transporter-2 inhibitors (SGLT2-I ) like SENVELGO® (velagliflozin oral solution)], and what veterinarians and veterinary technicians need to know about. From diagnosing a first-time diabetic to ensuring pet owner compliance and treatment, you don’t want to miss this podcast!

Today’s VETgirl podcast is sponsored by Boehringer Ingelheim. Boehringer’s Animal Health provides first-in-class innovation for preventing and treating disease in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health.

Today’s VETgirl podcast is sponsored by Boehringer Ingelheim. Please note that the opinions in this podcast are expressed by the speaker(s)/sponsor(s), and not directly endorsed by VETgirl. Note: Dr. Behrend was compensated for her participation in this podcast.

SENVELGO® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. PROZINC® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. US-PET-0424-2024

IMPORTANT SAFETY INFORMATION: SENVELGO® (velagliflozin oral solution) is for use in cats only and is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. Before using this product, it is important to read the entire product insert, including the boxed warning.

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO. Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. For more information, please see full prescribing information.

IMPORTANT SAFETY INFORMATION: PROZINC® (protamine zinc recombinant human insulin) is for use in cats and dogs only. The most common insulin-related side effect is hypoglycemia. PROZINC is contraindicated during episodes of hypoglycemia and in animals sensitive to protamine zinc recombinant insulin or any other ingredients in PROZINC. For more information, please see full prescribing information.

Only VETgirl members can leave comments. Sign In or Join VETgirl now!